Quelltext der Seite Nexavar2659438

CytoDyn has been meeting with Principle Investigator Dr. Jay Lalezari at Quest Clinical Research in regards to finalizing their work towards a 'Phase 2' trial of 'Cytolin', which is an immune therapy. It works along with our human immune systems, not to cure, but to control, the HIV infection. It's full of promise, and this is known because it was actually used about 2 full years before the 'antiretroviral cocktails' came out.[http://www.avastina.com nexavar]

The main goal of this meeting is to decide on how to proceed in order to get Cytolin approved by the FDA. Standards for AIDS treatments grow with each passing year, as new studies and new drugs evolve. It's hoped that Cytolin can help to control the HIV and thus delay the need for someone to begin the antiretroviral therapy.

In essence, Cytolin is a monoclonal antibody. It's basically antibodies from mice. Researchers believe that there's a flaw in the human immune system. That's because only humans get sick from the HIV virus. Animals get the virus, but we get sick, and they don't. Thus the conclusion that our immune systems aren't all they should be. They believe that Cytolin will 'correct' the immune system flaw, which is not the same as they've been doing, trying to 'reconstitute' the immune system.

The success for Cytolin looks good, but getting it approved is an uphill battle. The FDA requested a test from CytoDyn in which CytoDyn had to respond that the request was impossible to fulfill. But the commitment of CytoDyn has not been hampered. They have give their response to the FDA and under Section 117 (C)(3) of the Food and Drug Modernization Act of 1997, they have only 30 days upon receipt of a complete response, to act on it.